Open Targets


NAR Molecular Biology Database Collection entry number 1991
Gautier Koscielny; Peter An; Denise Carvalho-Silva; Jennifer A. Cham; Luca Fumis; Rippa Gasparyan; Samiul Hasan; Nikiforos Karamanis; Michael Maguire; Eliseo Papa; Andrea Pierleoni; Miguel Pignatelli; Theo Platt; Francis Rowland; Priyanka Wankar; A. Patricia Bento; Tony Burdett; Antonio Fabregat; Simon Forbes; Anna Gaulton; Cristina Yenyxe Gonzalez; Henning Hermjakob; Anne Hersey; Steven Jupe; Senay Kafkas; Maria Keays; Catherine Leroy; Francisco-Javier Lopez; Maria Paula Magarinos; James Malone; Johanna McEntyre; Alfonso Munoz-Pomer Fuentes; Claire O'Donovan; Irene Papatheodorou; Helen Parkinson; Barbara Palka; Justin Paschall; Robert Petryszak; Naruemon Pratanwanich; Sirarat Sarntivijal; Gary Saunders; Konstantinos Sidiropoulos; Thomas Smith; Zbyslaw Sondka; Oliver Stegle; Y. Amy Tang; Edward Turner; Brendan Vaughan; Olga Vrousgou; Xavier Watkins; Maria-Jesus Martin; Philippe Sanseau; Jessica Vamathevan; Ewan Birney; Jeffrey Barrett; Ian Dunham
Open Targets, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK
GSK, Medicines Research Center, Gunnels Wood Road, Stevenage, SG1 2NY, UK
Biogen, Cambridge, MA 02142, USA
European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK
Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, UK
National Center for Protein Research, No. 38, Life Science Park Road, Changping District, 102206 Beijing, China

Database Description

Open Targets has designed and developed a data integration and visualization platform that provides evidence about the association of known and potential drug targets with diseases. The platform is designed to support identification and prioritization of biological targets for follow-up. Each drug target is linked to a disease using integrated genome-wide data from a broad range of data sources. The platform provides either a target-centric workflow to identify diseases that may be associated with a specific target, or a disease-centric workflow to identify targets that may be associated with a specific disease. Users can easily transition between these target- and disease-centric workflows.

References

Open Targets: a platform for therapeutic target identification and validation Gautier Koscielny; Peter An; Denise Carvalho-Silva; Jennifer A. Cham; Luca Fumis; Rippa Gasparyan; Samiul Hasan; Nikiforos Karamanis; Michael Maguire; Eliseo Papa; Andrea Pierleoni; Miguel Pignatelli; Theo Platt; Francis Rowland; Priyanka Wankar; A. Patricia Bento; Tony Burdett; Antonio Fabregat; Simon Forbes; Anna Gaulton; Cristina Yenyxe Gonzalez; Henning Hermjakob; Anne Hersey; Steven Jupe; Senay Kafkas; Maria Keays; Catherine Leroy; Francisco-Javier Lopez; Maria Paula Magarinos; James Malone; Johanna McEntyre; Alfonso Munoz-Pomer Fuentes; Claire O'Donovan; Irene Papatheodorou; Helen Parkinson; Barbara Palka; Justin Paschall; Robert Petryszak; Naruemon Pratanwanich; Sirarat Sarntivijal; Gary Saunders; Konstantinos Sidiropoulos; Thomas Smith; Zbyslaw Sondka; Oliver Stegle; Y. Amy Tang; Edward Turner; Brendan Vaughan; Olga Vrousgou; Xavier Watkins; Maria-Jesus Martin; Philippe Sanseau; Jessica Vamathevan; Ewan Birney; Jeffrey Barrett; Ian Dunham Nucleic Acid s Research 2016; http://dx.doi.org/10.1093/nar/gkw1055


Oxford University Press is not responsible for the content of external internet sites